NO318099B1 - Anvendelse av Tumorcytotoksisk Faktor-II for fremstilling av et terapeutisk middel til behandling av hyperkolesterolemi og til okning av aktiviteten til lechitinkolesterolacyltransferase - Google Patents
Anvendelse av Tumorcytotoksisk Faktor-II for fremstilling av et terapeutisk middel til behandling av hyperkolesterolemi og til okning av aktiviteten til lechitinkolesterolacyltransferase Download PDFInfo
- Publication number
- NO318099B1 NO318099B1 NO19963551A NO963551A NO318099B1 NO 318099 B1 NO318099 B1 NO 318099B1 NO 19963551 A NO19963551 A NO 19963551A NO 963551 A NO963551 A NO 963551A NO 318099 B1 NO318099 B1 NO 318099B1
- Authority
- NO
- Norway
- Prior art keywords
- tcf
- therapeutic agent
- treatment
- cholesterol
- serum
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 21
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 6
- 108010094028 Prothrombin Proteins 0.000 title claims description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 title claims description 3
- 231100000433 cytotoxic Toxicity 0.000 title claims description 3
- 230000001472 cytotoxic effect Effects 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 6
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 title description 2
- 108010054082 Sterol O-acyltransferase Proteins 0.000 title description 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 claims description 19
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000004930 Fatty Liver Diseases 0.000 abstract description 12
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 12
- 208000010706 fatty liver disease Diseases 0.000 abstract description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 230000004064 dysfunction Effects 0.000 abstract description 6
- 230000002124 endocrine Effects 0.000 abstract description 6
- 206010021024 Hypolipidaemia Diseases 0.000 abstract description 5
- 230000006735 deficit Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 208000037157 Azotemia Diseases 0.000 abstract description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract description 3
- 230000001919 adrenal effect Effects 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 230000002440 hepatic effect Effects 0.000 abstract description 3
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 208000009928 nephrosis Diseases 0.000 abstract description 3
- 231100001027 nephrosis Toxicity 0.000 abstract description 3
- 230000006016 thyroid dysfunction Effects 0.000 abstract description 3
- 208000009852 uremia Diseases 0.000 abstract description 3
- 208000035762 Disorder of lipid metabolism Diseases 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 71
- 235000012000 cholesterol Nutrition 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 26
- 241000700159 Rattus Species 0.000 description 22
- 150000002632 lipids Chemical class 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 230000009467 reduction Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 10
- 230000037356 lipid metabolism Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 208000017170 Lipid metabolism disease Diseases 0.000 description 7
- 108090001030 Lipoproteins Proteins 0.000 description 7
- 102000004895 Lipoproteins Human genes 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 206010008635 Cholestasis Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000007870 cholestasis Effects 0.000 description 5
- 231100000359 cholestasis Toxicity 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 235000020888 liquid diet Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- BDQNKCYCTYYMAA-UHFFFAOYSA-N 1-isocyanatonaphthalene Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1 BDQNKCYCTYYMAA-UHFFFAOYSA-N 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- VPIDXLJVGVBFOW-UHFFFAOYSA-N C=1C=[C-]PC=1 Chemical compound C=1C=[C-]PC=1 VPIDXLJVGVBFOW-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical group [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6337884A JPH08176007A (ja) | 1994-12-27 | 1994-12-27 | 脂質代謝異常治療剤 |
| PCT/JP1995/002707 WO1996020004A1 (en) | 1994-12-27 | 1995-12-27 | Therapeutic agent for disorder of lipid metabolism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963551D0 NO963551D0 (no) | 1996-08-26 |
| NO963551L NO963551L (no) | 1996-10-25 |
| NO318099B1 true NO318099B1 (no) | 2005-01-31 |
Family
ID=18312906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963551A NO318099B1 (no) | 1994-12-27 | 1996-08-26 | Anvendelse av Tumorcytotoksisk Faktor-II for fremstilling av et terapeutisk middel til behandling av hyperkolesterolemi og til okning av aktiviteten til lechitinkolesterolacyltransferase |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0754051B1 (fi) |
| JP (1) | JPH08176007A (fi) |
| KR (1) | KR100395695B1 (fi) |
| AT (1) | ATE247975T1 (fi) |
| AU (1) | AU710513B2 (fi) |
| CA (1) | CA2184248A1 (fi) |
| DE (1) | DE69531608T2 (fi) |
| DK (1) | DK0754051T3 (fi) |
| ES (1) | ES2201128T3 (fi) |
| FI (1) | FI115826B (fi) |
| HU (1) | HU220139B (fi) |
| NO (1) | NO318099B1 (fi) |
| NZ (1) | NZ298141A (fi) |
| TW (1) | TW480173B (fi) |
| WO (1) | WO1996020004A1 (fi) |
| ZA (1) | ZA9510981B (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| KR100568664B1 (ko) * | 1997-03-14 | 2006-06-13 | 다이이치세이야꾸 가부시끼가이샤 | 악액질 예방 및/또는 치료제 |
| CA2253629A1 (en) * | 1997-03-14 | 1998-09-24 | Snow Brand Milk Products Co., Ltd. | Agent for preventing and/or treating cachexia |
| AU6748198A (en) | 1997-04-11 | 1998-11-11 | Takeda Chemical Industries Ltd. | Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use |
| JPH1129493A (ja) * | 1997-07-14 | 1999-02-02 | Snow Brand Milk Prod Co Ltd | 放射線障害予防及び／又は治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| DE69334281D1 (de) * | 1992-07-16 | 2009-05-28 | Daiichi Sankyo Co Ltd | TCF-II enthaltende medizinische Zusammensetzung |
-
1994
- 1994-12-27 JP JP6337884A patent/JPH08176007A/ja not_active Withdrawn
- 1994-12-27 NZ NZ298141A patent/NZ298141A/xx not_active IP Right Cessation
-
1995
- 1995-12-16 TW TW084113453A patent/TW480173B/zh not_active IP Right Cessation
- 1995-12-27 KR KR1019960704608A patent/KR100395695B1/ko not_active IP Right Cessation
- 1995-12-27 EP EP95942270A patent/EP0754051B1/en not_active Expired - Lifetime
- 1995-12-27 ES ES95942270T patent/ES2201128T3/es not_active Expired - Lifetime
- 1995-12-27 ZA ZA9510981A patent/ZA9510981B/xx unknown
- 1995-12-27 AU AU43550/96A patent/AU710513B2/en not_active Ceased
- 1995-12-27 DE DE69531608T patent/DE69531608T2/de not_active Expired - Fee Related
- 1995-12-27 CA CA002184248A patent/CA2184248A1/en not_active Abandoned
- 1995-12-27 HU HU9602341A patent/HU220139B/hu not_active IP Right Cessation
- 1995-12-27 DK DK95942270T patent/DK0754051T3/da active
- 1995-12-27 WO PCT/JP1995/002707 patent/WO1996020004A1/en active IP Right Grant
- 1995-12-27 AT AT95942270T patent/ATE247975T1/de not_active IP Right Cessation
-
1996
- 1996-08-26 FI FI963312A patent/FI115826B/fi active IP Right Grant
- 1996-08-26 NO NO19963551A patent/NO318099B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100395695B1 (ko) | 2004-02-14 |
| AU710513B2 (en) | 1999-09-23 |
| DK0754051T3 (da) | 2003-09-29 |
| CA2184248A1 (en) | 1996-07-04 |
| NO963551L (no) | 1996-10-25 |
| TW480173B (en) | 2002-03-21 |
| AU4355096A (en) | 1996-07-19 |
| HU9602341D0 (en) | 1996-10-28 |
| FI963312A (fi) | 1996-08-26 |
| JPH08176007A (ja) | 1996-07-09 |
| EP0754051B1 (en) | 2003-08-27 |
| KR970701058A (ko) | 1997-03-17 |
| DE69531608T2 (de) | 2004-02-19 |
| DE69531608D1 (de) | 2003-10-02 |
| ES2201128T3 (es) | 2004-03-16 |
| NZ298141A (en) | 2000-12-22 |
| ZA9510981B (en) | 1996-07-17 |
| WO1996020004A1 (en) | 1996-07-04 |
| FI115826B (fi) | 2005-07-29 |
| FI963312A0 (fi) | 1996-08-26 |
| ATE247975T1 (de) | 2003-09-15 |
| HUT76085A (en) | 1997-06-30 |
| HU220139B (hu) | 2001-11-28 |
| EP0754051A1 (en) | 1997-01-22 |
| NO963551D0 (no) | 1996-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamamoto et al. | Therapeutic effects of ML-236B in primary hypercholesterolemia | |
| Colombo et al. | Liver and biliary problems in cystic fibrosis | |
| Masunaga et al. | Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries | |
| KR100261114B1 (ko) | 히스톤을 함유하는 류마티스 관절염 치료제 조성물 | |
| NO318099B1 (no) | Anvendelse av Tumorcytotoksisk Faktor-II for fremstilling av et terapeutisk middel til behandling av hyperkolesterolemi og til okning av aktiviteten til lechitinkolesterolacyltransferase | |
| US5916874A (en) | Method for treating liver injury | |
| JPH05155780A (ja) | 溶性酵素によるリポタンパク質除去 | |
| Masunaga et al. | Amelioration of disordered hepatic protein synthesis by the deleted form of hepatocyte growth factor in models of liver failure in rats | |
| GB2092001A (en) | Pharmaceutical preparations comprising sodium fructose-1, 6-diphosphate for treatment of burn patients | |
| US6348495B1 (en) | Method for treating celiac disease | |
| EP0763360B1 (en) | Use of thrombomodulin for treating liver injury | |
| McClain et al. | Effect of sorbitol on psychomotor function: its use in alcoholic cirrhosis | |
| Maechler et al. | Importance of exogenous cholesterol in diabetic rats: effects of treatment with insulin or with an acyl-CoA: cholesterol acyltransferase inhibitor | |
| MXPA02000912A (es) | Uso de l-carnitina y sus derivados alcanoilo para la preparacion de un medicamento util para el tratamiento de pacientes que sufren nefropatias diabeticas o por insuficiencia metabolica. | |
| Salako et al. | The effects of porcine calcitonin on renal function in the rabbit | |
| JP2006160757A (ja) | 脂質代謝異常治療剤 | |
| Fukuo et al. | A lipid lowering drug (Bezafibrate) has a favorable effect on liver enzymes (Al-P and γ-GTP) | |
| RU2701159C1 (ru) | Способ коррекции метаболических нарушений и системы антиоксидантной защиты при метаболическом синдроме с жировым поражением печени | |
| CN115192574B (zh) | 乌头类生物碱在制备治疗gsdmd相关疾病药物中的应用 | |
| Smith | Recent work on vitamin B12 | |
| Ozawa et al. | The effect of CAPD on lipid abnormalities detected by apoproteins and ultracentrifugal lipid subfractions | |
| US20040138193A1 (en) | Oestrogen fatty acid monoester as a hypolipidaemic and antidiabetic agent | |
| CN116570704A (zh) | 小分子肽在制备治疗或预防慢性肾性蛋白尿的药物中的应用 | |
| EL | Isolation and chemistry of vitamin B12. | |
| HALE | The effect of the digestive secretions on the activity of digitalis and allied drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |